AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
Morgan Pressel's 18th annual Morgan & Friends event raised a record $1,022,000 to support the fight against breast cancer.
Inside Edition' reporter Alison Hall undergoes a double mastectomy, after discovering her breast cancer while on assignment.
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...
Technology could soon do more than assist doctors. Thanks to advancements in cancer-identifying AI, it could actively save ...
Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.
As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves ...
Breast cancer detection in its early stages significantly improves survival rates, according to medical experts. While ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback